References
- Al-Arouj M Assaad-Khalil S Buse J Recommendations for management of diabetes during Ramadan: update 2010 Diabetes Care 2010 33 8 1895 1902 20668157
- Amiel SA Dixon T Mann R Jameson K Hypoglycaemia in type 2 diabetes Diabet Med 2008 25 3 245 254 18215172
- Salti I Bénard E Detournay B EPIDIAR study group A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study Diabetes Care 2004 27 10 2306 2311 15451892
- Barnett AH Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy Curr Med Res Opin 2010 26 6 1333 1342 20370379
- Whitmer RA Karter AJ Yaffe K Quesenberry CP Selby JV Hypoglycemic episodes and risk of dementia in older patients with Type 2 diabetes mellitus JAMA 2009 301 15 1565 1572 19366776
- Kirkman MS Briscoe VJ Clark N Diabetes in older adults Diabetes Care 2012 35 12 2650 2664 23100048
- Ibrahim M Abu Al Magd M Annabi FA Recommendations for management of diabetes during Ramadan: update 2015 BMJ Open Diabetes Res Care 2015 3 1 e000108
- Schweizer A Halimi S Dejager S Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan Vasc Health Risk Manag 2014 10 15 24 24391442
- Keating GM Vildagliptin: a review of its use in type 2 diabetes mellitus Drugs 2010 70 16 2089 2112 20964454
- Schweizer A Dejager S Foley JE Shao Q Kothny W Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials Diabetes Obes Metab 2011 13 1 55 64 21114604
- Matthews DR Dejager S Ahren B Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study Diabetes Obes Metab 2010 12 9 780 789 20649630
- Ferrannini E Fonseca V Zinman B Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy Diabetes Obesity Metab 2009 11 2 157 166
- Sheen AJ DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials Diabetes Metab 2012 38 2 89 101 22197148
- Sheen AJ Paquot N Gliptin versus a sulfonylurea as add-on to metformin Lancet 2012 380 9840 450 452 22748818
- Halimi S Levy M Huet D Quere S Dejager S Experience with vildagliptin in type 2 diabetic patients fasting during ramadan in France: insights from the VERDI study Diabetes Ther 2013 4 2 385 398 23996548
- Hassanein M Hanif W Malik W Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulfonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study Curr Med Res Opin 2011 27 7 1367 1374 21568833
- Devendra D Gohel B Bravis V Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan Int J Clin Pract 2009 63 10 1446 1450 19678856
- Al Sifri S Basiounny A Echtay A 2010 Ramadan Study Group The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulfonylurea during Ramadan: a randomised trial Int J Clin Pract 2011 65 11 1132 1140 21951832
- Aravind SR Al Tayeb K Ismail SB 2009 Ramadan Study Group Hypoglycaemia in sulfonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study Curr Med Res Opin 2011 27 6 1237 1242 21506631
- Al-Arouj M Hassoun AA Medlej R The effect of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study Int J Clin Pract 2013 67 10 957 963 24001317
- Shete A Shaikh A Nayeem KJ Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan World J Diabetes 2013 4 6 358 364 24379927